Valeant gets to the heart of cardiovascular diseases to improve patient treatment
MONTREAL, Feb. 14, 2014 /CNW Telbec/ - Valeant Canada is proud to participate in ARTERIA, an innovative research program aiming to improve treatment for patients suffering from cardiovascular diseases.
ARTERIA's partners include the Montreal Heart Institute, pharmaceutical companies such as Valeant Canada, and the Government of Quebec.
"Cardiovascular diseases account for 30% of the causes of death in the world, and affect 1.3 million Canadians. We are proud to collaborate with world-class partners, and put our talents and efforts together in offering patients a more personalized treatment, adapted to their genetics. This project is a perfect example of how Valeant wants to get involved in research in Quebec and Canada. More than ever, we can say that the patient is at the heart of our efforts," says Valeant Canada President and General Manager Jacques Dessureault.
ARTERIA is an integrated approach that, in addition to gathering expertise from all partners involved, will include genetic and plasma biomarker analysis, and make use of state-of-the-art imaging technologies. It will help select patients who need a specific treatment. As a result, the medical team will be able to provide a more adapted patient care, increasing the efficacy of the treatment and reducing its side effects. While improving the efficacy and safety of several drugs, ARTERIA will help the Quebec healthcare system save money. It will create new jobs and encourage knowledge sharing among the partners.
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International Inc., a multinational specialty pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Canada can be found at www.valeantcanada.com.
SOURCE Valeant CanadaFor further information:
Valeant Canada Inc.